TURKOVAC
Sign in to saveAlso known as ERUCOV-VAC
Turkovac (pronunciation: Help:IPA/Turkish|) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University. __TOC__ == Clinical trials == In November 2020, Turkovac started on phase I trials with 44 participants in Turkey.
Key facts
- Drug.drug_name
- Turkovac
- Drug.type
- vaccine
- Drug.target
- SARS-CoV-2
- Drug.vaccine_type
- inactivated
- Drug.legal_status
- Full list of Turkovac authorizations
- Drug.routes_of_administration
- Intramuscular
- Drug.CAS_number
- 2695585-27-2
- Drug.synonyms
- Erucov-Vac
via Wikipedia infobox
~1 min read
Encyclopedic overview
3 sectionsContents
- Clinical trials
- Authorization
- References
Turkovac (pronunciation: Help:IPA/Turkish|) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University. __TOC__ == Clinical trials == In November 2020, Turkovac started on phase I trials with 44 participants in Turkey.
In February 2021, Turkovac started on phase II trials with 250 participants in Turkey.
Excerpted from Wikipedia’s “TURKOVAC” article, available under the CC BY-SA 4.0 licence.